<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01863173</url>
  </required_header>
  <id_info>
    <org_study_id>91-3502</org_study_id>
    <nct_id>NCT01863173</nct_id>
  </id_info>
  <brief_title>Effect of Metoprolol on Thalassemia Cardiomyopathy</brief_title>
  <official_title>The Effect of Metoprolol Succinate on the Cardiac Function of Patients With Thalassemia Cardiomyopathy a Double Blind Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      effect of B blocker was first evaluated in patient with cardiomyopathy not induced by
      ischemia and idiopathic which as the most common causes of cardiomyopathy. Effect of BB on
      Thalassemia cardiomyopathy was evaluated in this study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this clinical trial, 45 patients with thalassemia cardiomyopathy were randomized to
      receive either metoprolol (n = 26) or placebo (n = 19). Echocardiography and 6 minute walk
      test was performed at baseline and repeated after 6 months and the values were compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ejection fraction</measure>
    <time_frame>6 months</time_frame>
    <description>LV contractility</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 minutes walk test</measure>
    <time_frame>6 months</time_frame>
    <description>functional capacity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>endsystolic volume</measure>
    <time_frame>6 months</time_frame>
    <description>functional capacity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient compliance</measure>
    <time_frame>6 months</time_frame>
    <description>drug complication,</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>B Thalassemia</condition>
  <arm_group>
    <arm_group_label>metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient or intervention group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoprolol</intervention_name>
    <description>using B blocker in patient group</description>
    <arm_group_label>metoprolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo to control group</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  documented LVEF &lt; 50% by echocardiography

          -  B thalassemia

          -  No decompensated heart failure for at least 4 weeks (hospitalization for CHF,
             worsening lower extremity edema, worsening dyspnea on exertion, , and orthopnea)

          -  have no evidence of acute myocarditis and

          -  hemoglobin level above 7 gr‚ÅÑdL.

        Exclusion Criteria:

          -  pulse rate below 60/min

          -  systolic blood pressure less than 90 mmHg

          -  evidence of peripheral vascular disease

          -  major depression, history of asthma, PR interval more than 240 msec, second or third
             degree AV block

          -  major medical diseases including diabetes mellitus requiring insulin injection,
             hypothyroidism, hypoparathyroidism, chronic renal failure (glomerular filtration rate
             below 30 ml/min), hepatic cirrhosis, hepatitis-B and hepatitis-C, positive tests for
             human immunodeficiency virus, and other hemoglobinopathies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shiraz University of Medical Sciences</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Atiq M, Bana M, Ahmed US, Bano S, Yousuf M, Fadoo Z, Khurshid M. Cardiac disease in beta-thalassaemia major: Is it reversible? Singapore Med J. 2006 Aug;47(8):693-6.</citation>
    <PMID>16865210</PMID>
  </reference>
  <reference>
    <citation>Murphy CJ, Oudit GY. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail. 2010 Nov;16(11):888-900. doi: 10.1016/j.cardfail.2010.05.009. Epub 2010 Jul 3. Review.</citation>
    <PMID>21055653</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2013</study_first_submitted>
  <study_first_submitted_qc>May 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2013</study_first_posted>
  <last_update_submitted>May 22, 2013</last_update_submitted>
  <last_update_submitted_qc>May 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Javad Kojuri</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Thalassemia cardiomyopathy</keyword>
  <keyword>metoprolol succinate</keyword>
  <keyword>echocardiography</keyword>
  <keyword>six minute walk test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

